"The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor.
GCTB generally occurs in a"...
In the course of treatment with preparations containing the prothrombin complex, thromboembolic events may occur particularly after high doses and/or in patients with thrombotic risk factors.
After application of high doses (single infusion of 100 units per kg of body weight, and daily doses of 200 units per kg of body weight) of FEIBA VH (AICC), laboratory and/or clinical signs of DIC have occasionally been observed.
As with all human plasma products, any kind of allergic reaction may be seen ranging from mild, short-term urticarial rashes to severe anaphylactoid reactions. Administration of FEIBA VH (AICC), Vapor Heated should be discontinued immediately, if such signs appear. Allergic reactions should be treated with antihistamines and glucocorticoids. Shock should be treated in the usual way.
Read the Feiba Vh (anti-inhibitor coagulant complex, vapor heated) Side Effects Center for a complete guide to possible side effects
Additional Feiba Vh Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.